UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **August 4, 2026**

OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-38242	**26-1761833**
(Commission File Number)	(I.R.S. Employer Identification Number)
2850 Frontier Drive **Warsaw, Indiana**	**46582**
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: **(574) 268-6379**

Not Applicable
(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.00025 par value per share	KIDS	Nasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 7.01. Regulation FD Disclosure.

The executive officers of OrthoPediatrics Corp. have several upcoming presentations to representatives of investors and analysts. The officers intend to use the material filed as Exhibit 99.1 herewith, in whole or in part, as part of those presentations.

The information in this Item 7.01, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	OrthoPediatrics Corp. Investor Presentation dated August 2026
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

* * * * * *

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OrthoPediatrics Corp.

Date: August 4, 2026	By:	/s/ Daniel J. Gerritzen
		Daniel J. Gerritzen, General Counsel and Secretary


OrthoPediatrics®
2026
Investor
Presentation
www.OrthoPediatrics.com

Disclaimer

Forward-Looking Statements

All statements, other than statements of historical facts, contained in this quarterly report, including statements regarding our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward looking statements speak only as of the date of this report. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as the impact of widespread health emergencies, such as COVID 19 and respiratory syncytial virus, that may cause our results, activity levels, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements. Forward-looking statements may include, among other things, statements relating to: our ability to achieve or sustain profitability in the future; our ability to raise additional capital to fund our existing commercial operations, develop and commercialize new products and expand our operations; our ability to commercialize our products in development and to develop and commercialize additional products through our research and development efforts, and if we fail to do so we may be unable to compete effectively; our ability to generate sufficient revenue from the commercialization of our products to achieve and sustain profitability; our ability to comply with extensive government regulation and oversight both in the United States and abroad; our ability to maintain and expand our network of third-party independent sales agencies and distributors to market and distribute our products; and our ability to protect our intellectual property rights or if we are accused of infringing on the intellectual property rights of others; We cannot assure you that forward-looking statements will prove to be accurate, and you are encouraged not to place undue reliance on forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations expressed or implied by the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in our quarterly report, in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 4, 2026, and in other reports filed with the SEC that discuss the risks and factors that may affect our business. Other than as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, events or circumstances occurring after the date of this quarterly report.

Use of Non-GAAP Financial Measures

This presentation includes certain non-GAAP financial measures, such as free cash flow, adjusted diluted (loss) earnings per share and Adjusted EBITDA, which differ from financial measures calculated in accordance with U.S. generally accepted accounting principles ("GAAP"). Free cash flow, which we reconcile to "Net cash used in operating activities" is cash flow from operations increased by "Capital expenditures". Adjusted loss per share in this press release represents diluted loss per share on a GAAP basis, plus the accreted interest attributable to acquisition installment payables, restructuring charges, tariffs, European Union Medical Device Regulation fees increase, acquisition related costs, and minimum purchase commitment costs. We believe that providing the non-GAAP diluted loss per share excluding these expenses, as well as the GAAP measures, assists our investors because such expenses are not reflective of our ongoing operating results. Adjusted EBITDA in this release represents net loss, plus interest expense, net plus other income, income tax charge (benefit), depreciation and amortization, stock-based compensation expense, restructuring charges, European Union Medical Device Regulation fees increase, acquisition related costs, and the cost of minimum purchase commitments. The fair value adjustment of contingent consideration is associated with our estimates of the value of earn-outs in connection with certain acquisitions. The Company believes the non-GAAP measures provided in this earnings release enable it to further and more consistently analyze the period-to-period financial performance of its core business operating performance. Management uses these metrics as a measure of the Company's operating performance and for planning purposes, including financial projections. The Company believes these measures are useful to investors as supplemental information because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. Free cash flow is a non-GAAP financial measure and has limitations because it does not represent the cash flow available for management's use as it does not reflect capital expenditures which will likely recur in the future. Adjusted EBITDA is a non-GAAP financial measure and should not be considered as an alternative to, or superior to, net income or loss as a measure of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and it should not be construed to imply that the Company's future results will be unaffected by unusual or non-recurring items. In addition, the measure is not intended to be a measure of free cash flow for management's discretionary use, as it does not reflect certain cash requirements such as debt service requirements, capital expenditures and other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and other potential cash requirements. In evaluating these non-GAAP measures, you should be aware that in the future the Company may incur expenses that are the same or similar to some of the adjustments in this presentation. The Company's presentation of non-GAAP free cash flow, diluted loss per share or Adjusted EBITDA should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company's GAAP results in addition to using these adjusted measures on a supplemental basis. The Company's definition of these measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation. The schedules below contain reconciliations of Net cash used in operating activities to Free cash flow (Non-GAAP), GAAP diluted loss per share to non-GAAP diluted loss per share and net loss to non-GAAP Adjusted EBITDA.

OrthoPediatrics was founded on the **cause** of impacting the lives of children with orthopedic conditions

+ 1,382,000

pediatric patients treated since inception[1]

01 Children's **unique clinical conditions**

02 Existing solutions are **re-purposed from adult implants**

03 Limited development of **new technologies**

04 No **specialized sales force** in Pediatric Orthopedics

05 Limited industry support of clinical **education**

Re-Purposed Adult Plate
Screws through growth plate



1. **Product development focused** exclusively on pediatric patients
2. **Broadest pediatric specific portfolio** in the industry
3. Delivering first in market **novel surgical solutions**
4. Only global **commercial channel to market**
5. Leading provider of surgeon **clinical education**

OrthoPediatrics **Solution**

PediLoc Femur

Screws parallel to growth plate

- Enhance surgeon confidence
- Increase surgical efficiency
- Improve surgical accuracy

Only Focused Pediatric Orthopedic Company

Innovative Technology

- **+90** unique pediatric systems
- Consistent **cadence** of innovative product launches
- Expanding suite of **enabling** technologies
- Internal **R&D**, acquisitions, and partnerships

Commercial Execution

- **Only** global sales & distribution channel
- Serve **100% of top children's hospitals** in the U.S.
- **~240** domestic field representatives
- Sell in **over 75** countries around the world

Clinical Education

- **Commitment** to clinical education
- Leading **sponsor** of critical pediatric medical societies
- **>700** clinical product/education events per year
- **Founder** of Foundation of Advancing Pediatric Orthopedics

Consistent YoY Growth
Since Inception[1]

[1] Excluding COVID-impacted 2020

Total Global **Addressable Market** – **$6.2B**

U.S. Addressable Market[1] — $2.8B



Competitive Dynamics

01 Large incumbents repurpose adult implants

02 Require specialized sales force

03 Lack of focus on pediatric conditions

[1] Management's Estimate as of January 2025 updates to IMS data from 2016

Strategic **Pillars**

01 **Laser focus** on high-volume Children's Hospitals that treat majority of pediatric patients

02 Provide a **broad product portfolio** uniquely designed to treat children, surround pediatric orthopedic surgeons covering their needs

03 **Deploy** instrument sets and provide unparalleled sales support

04 Expand addressable market through aggressive investment in **R&D and select M&A opportunities**

05 **Train** next generation of pediatric orthopedic surgeons

01 **Focus on High-Vol Children's Hospitals**

Current US **Target Market – $1.6B**

Current U.S. Target Market[1] — $1.6B



Comments

01 ~1,520 Fellowship Trained Pediatric Surgeons

02 Majority of Pediatric Centers are Teaching Hospitals

03 Centers Treat Most Complex Pediatric Conditions

04 ~80% of Pediatric Surgeons time is Non-Surgical

[1] Management's Estimate as of January 2025 updates to IMS data from 2016


02 Provide Broad Product Portfolio
A History of Steady Innovation in Pediatrics
20 Years of Foundation Building
LAUNCH
Cannulated Screws
LAUNCH
PediNail™ System
LAUNCH
Hip Systems
LAUNCH
RESPONSE™ Scoliosis
ACQUIRE
Orthex® External Fixation
ACQUIRE
MD Orthopedics® Bracing
2008
2012
2016
2020
2025
90+ Systems
Broadest Portfolio across:
Trauma & Def
Scoliosis
Sports Med
External Fixation
Specialty Bracing
Enabling Tech
2026 // Investor Presentation
OrthoPediatrics
10

02 Provide a Broad Product Portfolio

Strong Foundation of Implants



02 **Provide a Broad Product Portfolio**

Strong Innovation & R&D

Surgeon-led Innovation
- New products originate from unmet clinical needs identified by pediatric orthopedic surgeons

Building Platforms
- Focus on platform & product family development rather than isolated products

Multi-year super cycle
- Entered a multi-year product super cycle, with multiple launches expected over several years

Trauma & Deformity
- 3P™ Small | Mini
- PNP | Retro
- 3P™ | Knee
- PNP | SD
- Pin to Bar Ex-Fix

Scoliosis
- VerAxis™ Scoliosis
- eLLi™

OPSB
- Tractor Fix

Enabling Tech
- Predictive Planning

Entering a "Super-Cycle" of Differentiated Product Launches

Entering a "Super-Cycle" of Differentiated Product Launches

03 **Expand Instr. Sets & Sales Personnel**

Total Revenue ($M)



Accelerating Sales Growth Post-IPO
Through Strategic Investment and Innovation

	2016	2025	CAGR
U.S. Independent Sales Consultants	90	232	11%
Instrument Set Deployments	$7M	$17	10%
Unique Pediatric Systems	17	87	20%
Intl. Independent Sales Agencies	0	16	Fav

- Accelerate Revenue Growth
- Increase Hospital Penetration
- Improve Profitability
- Leverage Balance Sheet

[1] Impacted by COVID

03 Expand Instr. Sets & Sales Personnel



[1] Boston O&P Acquisition

[2] Represents the midpoint of the Company's 2026 revenue guidance range of $265.0 to $269.0 million and expected annual set deployment

Improving ROI on Sets Deployed

01 **Super Cycle Product Launches**
- Products with defined clinical needs & stronger financial profile (higher ASPs and gross margins, less capital required)

02 **Higher Utilization**
- Market share gains and ramping in utilization of previous deployments creates leverage

03 **Platform Systems**
- Systems designed to utilize similar parts produces platform synergies and capital efficiencies


04 Expand Market with M&A
Strategic Acquisitions & Partnerships
Partnership
Acquisition
FIREFLY
ApiFix
MD ORTHOPAEDICS
Pega Medical
MedTek Concepts
boston
2017
2019
2020
2021
2022
2023
2024
2026
ORTHEX
7D Surgical
ORA Medical
RHINO
OSSIO
2026 // Investor Presentation
OrthoPediatrics
17

Aggressive market-based clinic expansion strategy

18 new markets by 2027 (27 total)

Accelerate R&D with increasing number of YoY launches

Launch 4 products in 2024 and 5 in 2025

Scale OPSB selling channel and sales force – grow with current portfolio of products

Doubling size of the sales channel

Pace of Market Expansion

+4 markets in 2025

+6 markets in 2026

+8 markets in 2027

OPSB clinics expected to be in 27 territories in 2027 out of 80 target territories

OPSB ROI and Timing for Clinic Expansion

	Greenfield	Acqui-Hire
Initial Investment	$200k-$500k	$500K-$1M
EBITDA Goal	Positive EBITDA by end of first full year	Positive EBITDA by end of first full year
FCF Goal	After first full year	Within first year
ROI Goal	Break even ROI by Year 3	Break even ROI by Year 5
Time to Ramp	6 months for licensure, insurance, lease, clinicians, training, etc.	Immediate licensure, insurance, location, clinicians, training etc.
IRR	40%	25%

1-4 Clinics per market expected

04 **Expand Market with M&A**

OPSB Opportunity – **$2.2B**

U.S. Potential Target Market [1] — $1.0B



Levity Device for Gait Assist

Dynamic Femur Fracture (DF2) Brace

[1] Management's Estimate as of January 2026

05 Train Next-Gen Surgeons

Physician Education and Awareness

Supporting more than 20 fellowships

01 **OP Hands-on sales training and support**

- Annually invests 3% of sales on clinical education
- Conducts >700 product/training sessions per year

02 **Market development**

- Fosters early relationships with young surgeons and fellows to drive sustainable growth

03 **Continuous education**

- Major Sponsor of the prominent pediatric orthopedic societies



>90 Differentiated Pediatric Systems Driving Growth
Trauma & Deformity
Pediatric Systems
Revenue
14
68
2016
2025
+19% CAGR
$26.8
$166.3
2016
2025
+22% CAGR
70% of Revenue
Scoliosis
Pediatric Systems
Revenue
3
17
2016
2025
>4X Growth
$9.3
$66.0
2016
2025
>6X Growth
28% of Revenue
2025 Revenue by Product Family
Trauma & Deformity
Scoliosis
Sports Medicine
2026 // Investor Presentation
OrthoPediatrics
23


Strong History of Y/Y Growth ($M)
400% 137% 44% 58% 22% 21% 31% 20% 22% 26% 26% -2% 38% 25% 22% 38% 15% 13%
$0.6 $3.0 $7.1 $10.2 $16.1 $19.6 $23.7 $31.0 $37.3 $45.6 $57.6 $72.6 $71.1 $98.0 $122.3 $148.7 $204.7 $236.3 $267.0
2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020[1] 2021 2022 2023 2024 2025 2026[2]
U.S.
International
2026 // Investor Presentation
OrthoPediatrics
24
[1] Impacted by COVID
[2] Represents the midpoint of the Company's 2026 revenue guidance range of $265.0 to $269.0 million

Revenue Seasonality

Seasonality Drives Stronger Performance in Summer Months and Holiday Periods



Income Statement Summary

($ in Millions)

	FY2023	FY2024	FY2025	2Q 2025	2Q 2026
Revenue	$148.7	$204.7	$236.3	$61.1	$70.5
Growth %	22%	38%	15%	16%	15%
Gross profit	$111.3	$148.6	$172.7	$44.0	$52.4
Margin %	75%	73%	73%	72%	74%
Operating expenses	$138.0	$183.6	$211.9	$54.7	$56.4
Operating loss	($26.8)	($35.0)	($39.2)	($10.7)	($4.1)
Net (loss) income	**($21.0)**	**($37.8)**	**($39.6)**	**($7.1)**	**($7.2)**
EPS diluted	**($0.92)**	**($1.64)**	**($1.69)**	**($0.30)**	**($0.30)**

Adjusted EBITDA Reconciliation

($ in Millions)

	Three Months Ended June 30,	
	2025	**2026**
Net loss	($7.1)	($7.2)
Interest expense, net	1.1	2.5
Other expense (income), net	(4.7)	0.3
Income tax charge	-	0.3
Depreciation and amortization	5.1	5.7
Stock-based compensation	5.3	4.2
Restructuring charges	3.0	-
Tariffs	0.6	0.2
Acquisition related costs	0.5	0.8
Minimum purchase commitment cost	0.3	-
Adjusted EBITDA	**$4.1**	**$6.8**

Adjusted EPS Reconciliation

	Three Months Ended June 30,	
	2025	**2026**
Loss per share, diluted (GAAP)	($0.30)	($0.30)
Tariffs	0.03	0.01
Restructuring charges	0.13	-
Acquisition related costs	0.02	0.03
Minimum purchase commitment cost	0.01	-
Adjusted loss per share, diluted (non-GAAP)	**($0.11)**	**($0.26)**


Free Cash Flow ($M)
Total Year
$30
$20
$10
$0
($10)
($20)
($30)
($40)
($50)
($42)
($15)
$9
$(21)
$(30)
$15
$(17)
$(13)
2024
2025
Cash Used For Working Capital
Sets Deployed
Adj. EBITDA
Quarterly
$15
$10
$5
$0
($5)
($10)
($15)
($20)
($25)
($30)
($13.9)
($3.1)
$4
$(5)
$(13)
$7
$(3)
$(7)
2Q25
2Q26
Cash Used For Working Capital
Sets Deployed
Adj. EBITDA
YTD
($22.2)
($8.1)
$4
$(8)
$(18)
$9
$(5)
$(12)
YTD 25
YTD 26
Cash Used For Working Capital
Sets Deployed
Adj. EBITDA
2026 // Investor Presentation
OrthoPediatrics
29

($ in Millions)
As of June 30, 2026

Assets	
Cash, cash equivalents & short-term investments	$47.9
Accounts receivable	61.0
Inventory (net)	137.6
Other current assets	6.1
Total Current Assets	**252.5**
PP&E (net)	48.6
Intangibles and goodwill	210.3
Total Assets	**$511.4**

Liabilities	
Accounts payable	$22.2
Debt	99.6
Accrued comp. & other liab.	41.8
Acquisition pay. & cont. consideration	4.1
Paid-in capital	633.4
Accumulated deficit (net)	(293.1)
Accumulated other comprehensive loss	3.2
Total Liabilities / Equity	**$511.4**

Full Year 2026 Guidance

($ in Millions)

2026 Guidance

	FY2026
Revenue	$265.0 to $269.0
Adjusted EBITDA	~$25.0
Free Cash Flow	Breakeven

Assumptions

	FY2026
2026 Total Revenue Growth %	12% to 14%
Set Deployment	~$10.0

01 Only diversified company focused exclusively on pediatric orthopedics

02 Large, underpenetrated market opportunity in pediatrics

03 Highly concentrated customer base with targeted commercial strategy

04 Broad product portfolio with innovative solutions

05 Only provider committed to pediatric clinical education

06 Dynamic, award-winning corporate culture

07 Proven commercial execution and attractive financial profile

2850 Frontier Drive • Warsaw, IN 465852
ph: 574.268.6379 or 877.268.6339
fax: 574.268.6302
www.OrthoPediatrics.com